Neuphoria Therapeutics reported cash from operations of -$3.37M and free cash flow of -$3.37M for the quarter ended Mar 2026, down 129.4% year over year. This cash flow statement covers 13 quarters of results from Jun 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2022 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Net Income | -5.47M | -4.55M | -2.78M | 1.12M | -0.80M | -1.94M | 11.26M | -15.16M | -9.91M | 1.86M | -0.51M | ||
| Share-based CompensationStock Comp. | 56.63M | 78.34M | 0.14M | 0.75M | 0.04M | 0.11M | 97.43M | 0.05M | 0.05M | 0.13M | 0.14M | 0.14M | 0.30M |
| Deferred Taxes | -0.03M | -0.03M | -0.03M | -0.03M | -0.13M | 0.01M | -0.08M | -0.27M | -0.03M | -0.03M | -0.03M | ||
| Gains from Investment SecuritiesGains Investment | -0.34M | -2.97M | -0.88M | 1.08M | 1.81M | 4.39M | -5.38M | -0.26M | |||||
| Cash from OperationsCash from Ops. | -4.43M | -3.95M | -3.30M | -3.01M | -4.43M | -3.36M | 11.45M | -3.56M | -3.80M | -6.43M | -3.37M | ||
| Depreciation, Depletion & Amortization | |||||||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M | ||
| Change in Working Capital | |||||||||||||
| Change in ReceivablesChange Receivables | 0.02M | -0.33M | -0.01M | 0.02M | -0.01M | -0.08M | -0.01M | -0.01M | -0.01M | 1.11M | 0.50M | ||
| Change in Account PayablesChange Payables | 0.88M | -0.87M | -0.87M | 1.66M | -0.92M | 0.20M | -0.79M | 0.58M | 0.22M | -0.85M | 0.11M | ||
| Change in Accured ExpensesChange Accured Exp. | -0.70M | 0.96M | -0.47M | 0.50M | -0.37M | -0.79M | 0.38M | 2.27M | 0.72M | -1.60M | -1.18M | ||
| Financing Activities | |||||||||||||
| Other financing activitiesOther financing | 409.00 | ||||||||||||
| Cash from Financing ActivitiesCash from Financing | 0.61M | 5.63M | 1.75M | 7.12M | -0.23M | -0.11M | 1.16M | 0.70M | 3.25M | 14.66M | |||
| Change in Capital Stock | |||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 28.81M | 5.84M | 0.04M | 0.05M | 0.03M | ||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 6.26M | 0.29M | 1.44M | 2.12M | 0.82M | 0.70M | 3.25M | 14.66M | |||||
| Additional items | |||||||||||||
| Exchange Rate EffectFX Effect | -0.15M | 0.34M | -0.19M | 0.07M | 0.14M | -0.28M | 0.08M | 0.05M | -0.02M | 0.30M | 0.53M | ||
| Change in Cash | -3.82M | 1.87M | -1.73M | 4.18M | -4.52M | -3.75M | 12.70M | -2.83M | -0.56M | 8.52M | -2.81M | ||
| Free Cash FlowFCF | -4.43M | -3.95M | -3.30M | -3.01M | -4.43M | -3.36M | 11.45M | -3.56M | -3.80M | -6.43M | -3.37M | ||
| Net Cash FlowNCF | -3.82M | 1.68M | -1.55M | 4.11M | -4.66M | -3.47M | 12.62M | -2.86M | -0.55M | 8.23M | -3.37M |